Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 158Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

ORIGINAL ARTICLE

Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial

Gupta Brij Mohan, Zargar Samir H, Arora Manu, Tandon Vishal R

Year : 2016| Volume: 7| Issue : 1 | Page no: 45-50

   This article has been cited by
 
1 Incorporating clinical research into recommendations for addressing global mental health needs: Updating the World Health Organizationęs Essential Medicines List
Iona K. Machado,Csilla Lippert,Michael J. Ostacher
Comprehensive Psychiatry. 2021; : 152245
[Pubmed]  [Google Scholar] [DOI]
2 Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder
Mahmoud S. Abdallah,Ahmed N. Ramadan,Hend Omara-Reda,Noha O. Mansour,Mohamed A. Elsokary,Hozaifa K. Elsawah,Shimaa Abdelsattar Zaki,Hend E. Abo Mansour,Esraa M. Mosalam
CNS Neuroscience & Therapeutics. 2021;
[Pubmed]  [Google Scholar] [DOI]
3 Efficacy and safety of escitalopram in treatment of severe depression in Chinese population
Tianmei Si,Gang Wang,Fude Yang,Yiru Fang,Maosheng Fang,Jijun Li,Jicheng Dong,Xinhua Shen,Jianmin Zhuo,Qing Rui,Jinan Wang,Hu Cuili
Metabolic Brain Disease. 2017; 32(3): 891
[Pubmed]  [Google Scholar] [DOI]

 

Read this article